Lots of interesting abstracts and cases were submitted for TCTAP 2024. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-016
1 Year Clinical Outcomes of Patients Treated With DynamX Bioadaptor Drug Eluting Stent in Primary Percutaneous Coronary Intervention
By Hee Hwa Ho, Cliff Li, Randal Jun Bang Low, Thet Khaing, Bharat Khialani, Jinhyun Lee, Deanna Zin Lin Khoo, Jason Kwok Kong Loh, Fahim Jafary
Presenter
Hee Hwa Ho
Authors
Hee Hwa Ho1, Cliff Li1, Randal Jun Bang Low1, Thet Khaing1, Bharat Khialani1, Jinhyun Lee1, Deanna Zin Lin Khoo1, Jason Kwok Kong Loh1, Fahim Jafary1
Affiliation
Tan Tock Seng Hospital, Singapore1
View Study Report
TCTAP A-016
ACS/AMI
1 Year Clinical Outcomes of Patients Treated With DynamX Bioadaptor Drug Eluting Stent in Primary Percutaneous Coronary Intervention
Hee Hwa Ho1, Cliff Li1, Randal Jun Bang Low1, Thet Khaing1, Bharat Khialani1, Jinhyun Lee1, Deanna Zin Lin Khoo1, Jason Kwok Kong Loh1, Fahim Jafary1
Tan Tock Seng Hospital, Singapore1
Background
Primary percutaneous coronary intervention (PPCI) with new generation drug-eluting stents (DES) is the preferred reperfusion therapy for ST-elevation myocardial infarction (STEMI).
The DynamX Bioadaptor drug-eluting stent (DES) is a new class of treatment for coronary artery disease with the unique property of adapting to vessel physiology. It has the potential to allow the vessel to expand with restoration of vasomotion resulting in better clinical outcomes.
There is limited data on the outcomes of DynamX Bioadaptor DES in the setting of primary percutaneous coronary intervention (PPCI).
We evaluated the clinical efficacy and safety of DynamX Bioadaptor DES in PPCI and report on the 1-year clinical outcomes.
Methods
From 2021 to 2022, 40 STEMI patients (33 male, mean age 56.4 ±10.7 years) with de novo coronary lesions were treated with the DynamX Bioadaptor DES ( Elixir Medical, California, USA) during PPCI.
The primary end-point was a major adverse cardiac event (MACE) defined as a composite of cardiovascular mortality, re-infarction and target lesion revascularization (TLR) within 1 year of follow-up.
Results
The majority of patients presented with inferior STEMI (54%) with the right coronary artery being the most common target vessel for PPCI.
The majority of patients had single vessel disease (48%) on coronary angiography with 15% of patients having underlying diabetes mellitus. The mean left ventricular ejection fraction was 44 ± 9% and 2.5% of patients presented with cardiogenic shock.
96% of PPCI was performed by transradial intervention and the use of intracoronary imaging was 75% ( mostly intravascular ultrasound). Thrombus aspiration was performed in 40% of patients and the use of glycoprotein 2b/3a inhibitors was 83%.
An average of 1.1 + 0.35 stent were used per patient with mean stent diameter of 3.1 ± 0.4 mm and average length of 28.6 ± 7.6 mm.
At 30-day follow-up, there was no death. There was also no reported reinfarction, TLR and stent thrombosis.
At 1-year follow-up, there was no case of cardiovascular death, re-infarction, TLR or stent thrombosis.
Conclusion
Our experience showed that the use of DynamX Bioadaptor DES in PPCI was safe and feasible and safe, with a reported 1-year MACE rate of 0%.